Expanded Access Use of Cemiplimab in Patients With Solid Tumors
NCT06132191 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-11-20
Summary
Provide expanded access of cemiplimab in patients with solid tumors
Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Basal Cell Carcinoma (BCC)
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
NCT04315701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
NCT05302297 ·Status: COMPLETED
-
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
NCT03889912 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
NCT04154943 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
NCT00055562 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
NCT06981325 ·Status: RECRUITING ·Phase: PHASE2
-
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
NCT06052852 ·Status: TERMINATED ·Phase: PHASE1
-
CemiplimAb Survivorship Epidemiology
NCT03836105 ·Status: COMPLETED
-
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
NCT04242173 ·Status: TERMINATED ·Phase: PHASE2
-
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 ·Status: RECRUITING
-
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
NCT04526899 ·Status: COMPLETED ·Phase: PHASE2
-
Cemiplimab/Peg-Interferon-α in Advanced CSCC
NCT05729139 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172 ·Status: SUSPENDED ·Phase: PHASE3
-
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
NCT04975152 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
NCT03696069 ·Status: COMPLETED
-
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
NCT04428671 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
NCT06384820 ·Status: WITHDRAWN ·Phase: PHASE2
-
Real World Study on the Use of Cemiplimab in Adult Patients in UK
NCT05493826 ·Status: COMPLETED
-
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
NCT02307149 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT06121180 ·Status: RECRUITING ·Phase: PHASE2